It was postulated that estimation of proinflammatory serum biomarkers such as high-sensitivity CRP (IL-6) in acute stroke would be highly beneficial in assessing the care pathway for patients and their treatment options, as the most important challenge facing physicians is to reduce the unacceptable burden of stroke (Bharosay et al. 2011). Here, IL6 is linked to Stroke.